Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach

N Kim, H Kim, W Park, WK Cho, TG Kim, YH Im… - Radiation …, 2023 - Springer
Aim Patients with locoregionally uncontrolled breast tumors are frequently referred for breast
palliative radiotherapy (PRT) to mitigate symptoms. We analyzed the outcomes following …

Aggressive local therapy for de novo metastatic breast cancer: Challenges and updates

B Liu, H Liu, M Liu - Oncology Reports, 2023 - spandidos-publications.com
Systemic therapy has been viewed as the mainstay for de novo metastatic breast cancer
(dnMBC). However, as dnMBC is highly heterogeneous both biologically and clinically, and …

Combination of olaparib with radiotherapy for triple‐negative breast cancers: one‐year toxicity report of the RADIOPARP phase I trial

P Loap, D Loirat, F Berger, K Cao… - … journal of cancer, 2021 - Wiley Online Library
Triple‐negative breast cancer (TNBC) cells are sensitive to PARP1 inhibitors in vitro. The
combination of Olaparib and radiotherapy for TNBC is currently evaluated in the Phase I …

[HTML][HTML] HR+/HER2− de novo metastatic breast cancer: a true peculiar entity?

R Torrisi, F Jacobs, C Miggiano, R De Sanctis… - Drugs in …, 2023 - ncbi.nlm.nih.gov
De novo metastatic breast cancer (dnMBC) accounts for~ 6–10% of all breast cancers and
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …

Primary-site local therapy for patients with de novo metastatic breast cancer: an educational review

SA Khan, S Schuetz, O Hosseini - Annals of surgical oncology, 2022 - Springer
Background Until 2001, the paradigm guiding the management of women with de novo
metastatic breast cancer (dnMBC) stipulated that primary-site locoregional therapy (PSLT) …

Breast surgery for patients with de novo metastatic breast cancer: A meta-analysis of randomized controlled trials

C Ren, J Sun, L Kong, H Wang - European Journal of Surgical Oncology, 2024 - Elsevier
The role of breast surgery in the treatment of patients with de novo metastatic breast cancer
(dnMBC) remains controversial, with conflicting trial results. We did a meta-analysis to …

[HTML][HTML] Effect of postoperative radiotherapy after primary tumor resection in de novo stage iv breast cancer: a multicenter retrospective study (Krog 19-02)

YJ Kim, YJ Kim, YB Kim, IJ Lee… - … : Official Journal of …, 2022 - synapse.koreamed.org
Purpose This study aimed to investigate the impact of postoperative radiotherapy (PORT) in
de novo metastatic breast cancer (dnMBC) patients undergoing planned primary tumor …

[PDF][PDF] Consenso Mexicano sobre diagnóstico y tratamiento del cáncer mamario

JC Sánchez, JEB Rocha, AE Valle, AP Chacón… - …, 2013 - consensocancermamario.com
El primer Consenso Nacional sobre Diagnóstico y Tratamiento del Cáncer Mamario se llevó
a cabo en septiembre de 1994, en Colima; sus conclusiones se difundieron ampliamente1 y …

Consenso mexicano sobre diagnóstico y tratamiento del cáncer mamario

J Cárdenas Sánchez - Gaceta mexicana de oncología, 2021 - scielo.org.mx
El primer Consenso Nacional sobre Diagnóstico y Tratamiento del Cáncer Mamario se llevó
a cabo en septiembre de 1994, en Colima; sus conclusiones se difundieron ampliamente1 y …

Actualisation des indications chirurgicales et des indicateurs de qualité et sécurité des soins dans la prise en charge des carcinomes mammaires invasifs

C Mathelin, S Brousse, M Schmitt, N Taris… - … Obstétrique Fertilité & …, 2024 - Elsevier
Résumé Objectifs La chirurgie mammaire est la pierre angulaire du traitement des cancers
du sein. Ses indications et ses modalités évoluent régulièrement. Dans une démarche …